IDEX (IEX) Q2 2024 earnings summary

Executive summary

• Q2 2024 sales were $807M, down 5% year-over-year and 4% organically, with adjusted EPS at $2.06, slightly above guidance, and net income up 2% to $141M.

• Gross margin improved 70 bps to 45.4% due to strong price/cost and productivity, offsetting lower volumes and higher employee costs.

• Free cash flow was $118M, down 2% year-over-year, with conversion rates remaining strong.

• Recent acquisitions (Mott Corporation, Subterra) and divestiture (Alfa Valvole) reflect ongoing portfolio optimization and expansion in material science and water analytics.

• Operating performance remained solid despite industrial softness, project delays, and market headwinds, with innovation and emerging market growth highlighted.

Financial highlights

• Q2 orders were $773M, up 2% year-over-year; sales were $807M, down 5% reported and 4% organically.

• Adjusted EBITDA was $224M, down from $241M, with margin at 27.8% (down 60 bps year-over-year, up 180 bps sequentially).

• Adjusted net income was $156M; reported net income $141M; adjusted EPS $2.06 (down 6% year-over-year).

• Free cash flow for Q2 was $118M, with a 75% conversion rate, and for six months was $254.3M.

• Price capture for Q2 was ~2%, with a price-cost spread of 100 bps, at the high end of annual targets.

Outlook and guidance

• Full-year 2024 organic sales expected to decline 1%-2% (prior: growth of 0%-2%); adjusted EBITDA margin revised to ~27% (prior: ~28%).

• Full-year GAAP EPS guidance: $6.85-$6.95 (prior: $7.13-$7.43); adjusted EPS: $7.80-$7.90 (prior: $8.15-$8.45).

• Q3 2024 organic sales expected to be flat to up 1% year-over-year; adjusted EPS guidance $1.85–$1.90.

• Free cash flow conversion for the year expected to exceed 100%.

• Management expects current cash, operations, and credit facility to be sufficient for foreseeable needs, including acquisitions.